Table 2.
Results of follow-up including frequency of changes and appearance of high-risk stigmata/worrisome features
| Follow-up Variables | Value |
|---|---|
| Follow-up time, median with range (months) | 55 (13–134) |
| Changes during follow-up, No. (%) | 97 (58.1%) |
| Appearance of high-risk stigmata, No. (%) | 3 (1.8%) |
| Enhanced mural nodule, No. (%) | 1 (0.6%) |
| MPD caliber ≥10 mm, No. (%) | 1 (0.6%) |
| Jaundice, No. (%) | 1 (0.6%) |
| Time to develop HRS, median with range (months) | 56 (45–60) |
| Appearance of worrisome features, No. (%) | 44 (26.3%) |
| Cyst size ≥3 cm, No. (%) | 21 (12.6%) |
| Cyst wall thickening, No. (%) | 12 (7.2%) |
| Mural nodule, No. (%) | 13 (7.8%) |
| MPD caliber 5–9 mm, No. (%) | 10 (6.0%) |
| Acute pancreatitis, No. (%) | 4 (2.4%) |
| Time to develop WFs, median with range (months) | 26 (4–132) |
| Additional features | |
| Cyst growth ≥5 mm, No. (%) | 59 (35.3%) |
| Appearance of new cysts, No. (%) | 56 (33.5%) |
| Mural nodule growth ≥2 mm, No. (%) | 2 (1.2%) |
| Appearance of new symptoms, No. (%) | 7 (4.2%) |
| Diagnosis of high-grade atypia on EUS-FNA, No. (%) | 4 (2.4%) |
EUS-FNA endoscopic ultrasound-guided fine-needle aspiration, HRS high-risk stigmata, MPD main pancreatic duct, WF worrisome feature